Wenemea
Wenemea is a startup company focused on developing a solution to monitor and manage chemotherapy-induced peripheral neuropathy (CIPN), a common side effect affecting breast cancer patients. Their solution involves a device for measuring nerve function and a data model utilizing AI/machine learning to predict the risk of developing CIPN. This allows for earlier intervention, improved medication, and enhanced quality of life for patients. The company originated as a spin-out from research at Aarhus University and has received support from various foundations and initiatives.
Wenemea
Wenemea is a startup company focused on developing a solution to monitor and manage chemotherapy-induced peripheral neuropathy (CIPN), a common side effect affecting breast cancer patients. Their solution involves a device for measuring nerve function and a data model utilizing AI/machine learning to predict the risk of developing CIPN. This allows for earlier intervention, improved medication, and enhanced quality of life for patients. The company originated as a spin-out from research at Aarhus University and has received support from various foundations and initiatives.